Drug intelligence / Profile preview

neocarzinostatin

Development stage
Unknown
Modality
Recombinant Proteins and Enzymes, Small Molecules
Administration
Intravenous
01

Overview

Neocarzinostatin is a **macromolecular chromoprotein enediyne antitumor antibiotic** produced by Streptomyces macromomyceticus or Streptomyces carzinostaticus[1][3][5][7]. It consists of a **potent, labile enediyne chromophore** non-covalently bound to a 113-amino-acid protein, which stabilizes the chromophore and releases it at target DNA[1][3][7]. The chromophore acts by undergoing reductive activation in cells, triggering a Bergman cyclization and generating a benzenoid diradical; this leads to **sequence-selective single- and double-strand DNA breaks**, inhibiting DNA synthesis and inducing cell cycle arrest and apoptosis[1][3][5][6][7]. Neocarzinostatin has **antibiotic activity against Gram-positive bacteria** and **antitumor activity in liver cancer, leukemia, bladder cancer, and other solid tumors**, but clinical use is limited mainly to Japan due to its instability and toxicity[1][2][3][5][7].

Brand names
Zinostatin
Other names
holoneocarzinostatinmitomalcin
02

Targets

DNA

Beyond the preview

Go deeper on neocarzinostatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on neocarzinostatin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call